PVL Staph aureus
Post for academic purposes only. It MUST NOT be used to make a clinical decision. For clinical advice, please discuss with your doctor.
Clinical Guide for Diagnosis and Management
In the UK, PVL genes are carried by < 2% of clinical S. aureus isolates
🔍 Clinical Features
Recognize skin/soft tissue infections and invasive disease presentations
⚠️ Risk Factors
5C model and high-risk populations and settings
🧪 Testing & Diagnosis
Sample collection, processing, and PVL testing protocols
🫁 Pneumonia Management
Necrotising pneumonia recognition and treatment protocols
🩹 SSTI Management
Skin and soft tissue infection treatment guidelines
🦴 Osteomyelitis
Deep-seated infection management and treatment options
🛡️ Infection Control
PPE requirements, isolation, and outbreak management
👨⚕️ Staff Management
Healthcare worker screening, decolonisation, and return-to-work
← Back to Menu
Clinical Features of PVL-SA
Skin and Soft Tissue Infections
- Suspect when: Recurrent skin and soft tissue infections
- Purulent eye infections
- Variable size lesions with/without necrosis
- Pain disproportionate to appearance
- Multiple cases in close contact settings
Invasive Infections
- Necrotising pneumonia - may follow flu-like symptoms
- Necrotising fasciitis
- Purpura fulminans
- Acute haematogenous osteomyelitis
- Osteoarticular infections in children
- Pyomyositis
Key Clinical Signs:
Haemoptysis and elevated inflammatory markers may accompany necrotising pneumonia
← Back to Menu
Risk Factors for PVL-SA
Remember the 5C Model:
Contaminated items
Shared towels, equipment
Close contact
Direct person-to-person contact
Crowding
Overcrowded living conditions
(Lack of) Cleanliness
Poor hygiene practices
Cuts
Compromised skin integrity
High-Risk Settings
- Households
- Close contact sports (wrestling, American football, rugby, judo)
- Military training camps
- Gyms
- Prisons
Typical Patient Profile:
Young, healthy people, students, athletes, and military personnel with no significant medical history
← Back to Menu
Testing for PVL
Sample Collection
- Wound swab or pus for skin/soft tissue infections
- Sputum/BAL for respiratory infections
- Blood culture for systemic infections
- Process samples as per national SMI
Clinical Hint:
If isolate is MRSA and ciprofloxacin sensitive, higher chance of being PVL positive
PVL Testing Process
- Grow Staphylococcus aureus from sample
- Send isolate to reference laboratory for PVL test
- Results guide treatment decisions
Outbreak Investigation
| Outbreak Type | Screening Medium | Notes |
|---|---|---|
| PVL MSSA | Non-selective agar (blood agar) | Standard screening approach |
| PVL MRSA | Selective medium (Mannitol Salt Agar, chromogenic media) | Do NOT use ciprofloxacin for MRSA selection |
← Back to Menu
Managing PVL Pneumonia
Initial Management:
Start treatment as per NICE CAP guidelines (NOT the old PVL guideline recommendations)
Clinical Suspicion Criteria
- Multilobular infiltrates
- Respiratory rate >30, Pulse rate >140
- Haemoptysis
- Leukopenia ± skin and soft tissue infection
- Young patient
- Recent flu-like illness or close contact
- High inflammatory markers, raised CK (pyomyositis)
Management Protocol
- Admit to intensive care/critical care
- Send urine for Pneumococcal & Legionella antigen
- Test for other causes (flu, pulmonary embolism)
- Take respiratory culture with appropriate PPE
- Take 2 sets of blood cultures, wound cultures
Empiric Antibiotic Treatment
Standard: Linezolid 600mg bd + Clindamycin 1.2g QDS
Severe disease/TSS: Add IVIG 2g/kg + Rifampicin 600mg bd
If Not Improving
- Check source control and alternative infection sources
- Check for other resistant pathogens
- Consider 2nd dose of IVIG
← Back to Menu
Managing Skin and Soft Tissue Infections
Important:
Most PVL Staph aureus in the UK are sensitive to flucloxacillin. Always perform sensitivity tests as per EUCAST, including D test for erythromycin-clindamycin.
Minor SSTI
Furunculosis, folliculitis, small abscesses/boils without cellulitis
- Usually no systemic antibiotics needed
- Exceptions: immunocompromised, infants, clinical deterioration
- Incision and drainage optimal for abscesses
Moderate SSTI
Cellulitis and larger abscesses (especially >5cm)
| Organism | Treatment Options |
|---|---|
| MSSA | • Flucloxacillin 500mg qds • Clindamycin 450mg qds |
| PVL-MRSA (outpatient) | • Rifampicin 300mg bd + Doxycycline 100mg bd • Rifampicin 300mg bd + Fusidic acid 500mg tds • Rifampicin 300mg bd + Trimethoprim 200mg bd • Clindamycin 450mg qds |
Severe Infection
- IV vancomycin, teicoplanin, daptomycin, or linezolid
- Tigecycline for broader polymicrobial cover (avoid if sepsis signs)
Severe with Toxic Shock/Necrotising Features
Triple therapy:
• Linezolid 600mg bd
• Clindamycin 1.2-1.8g qds
• Rifampicin 600mg bd
• Surgical debridement
• Treat for 10-14 days
Rifampicin Benefits:
Excellent tissue penetration, reaches intracellular staphylococci, synergistic with other antibiotics including linezolid
← Back to Menu
Managing Osteomyelitis and Deep-Seated Infections
Investigation
- Blood culture - two sets appropriately filled
- Inflammatory markers (WCC, CRP, ESR) and renal/liver function baseline
- Imaging: MRI/radio-isotope scan
- Assess for DVT
Treatment Options
| Category | Treatment |
|---|---|
| Preferred | • Teicoplanin 400-800mg IV q24h (after loading dose) • Vancomycin 1g IV q12h PLUS one of: • Gentamicin 5-7mg/kg IV once daily • Rifampicin 300mg PO twice daily • Sodium fusidate 500mg PO thrice daily |
| 2nd Choice | • Linezolid 600mg IV/PO q12h • Daptomycin 6-8mg/kg IV once daily (off-label) • Tigecycline 100mg loading, then 50mg IV q12h |
If MSSA confirmed:
Use sensitivity-guided agents that inhibit toxin production and have good bone penetration (e.g., Clindamycin + rifampicin or linezolid)
If MRSA positive or unknown:
Treat as MRSA regardless
Important Considerations
- Hospital assessment likely required with orthopaedic advice
- May require prolonged treatment and repeated surgery
- Monitor drug levels: Teicoplanin trough: 10-20 mg/L Vancomycin trough: 10-15 mg/L
- Linezolid maximum 4 weeks (peripheral neuropathy risk)
← Back to Menu
Infection Control
Standard Precautions
- Contact precautions (as per MRSA protocol, even for PVL-MSSA)
- Single room isolation
- Personal protective equipment (plastic apron and gloves)
- Meticulous hand hygiene
- Environmental cleaning
Necrotising Pneumonia PPE:
Healthcare workers must wear face and eye protection (surgical mask with integral eye protection) during intubation and respiratory care
Staff Exposure Protocol
If staff exposed during aerosol-generating procedure without appropriate PPE:
- Screen 3-7 days after exposure
- Advise to report symptoms to physician
- Managed by occupational health
Work Restrictions
Cannot work in:
Nursery, hospital, residential/care homes, food industry until all lesions healed
Other professions: May continue work with infected areas covered by clean, dry dressings
Screening and Decolonisation
Primary Case Screening
- Anterior nares and throat swabs
- Any suspicious lesions, including damaged skin
- Additional sites: perineum, axilla
Decontamination Protocol
Body wash: Chlorhexidine 4% or Triclosan 2% once daily for 5 days
Nasal: Mupirocin (Bactroban) three times daily for 5 days
Contact Management
- Close contacts with history of past infection: decolonise without prior screening
- Household contacts of necrotising pneumonia: 5-day topical decolonisation immediately
- Consider oseltamivir prophylaxis if index case had influenza
Notification Requirements
- Hospital cases: Notify infection control
- Suspected outbreak: Inform public health
- Staff involvement: Notify occupational health
← Back to Menu
Managing Healthcare Staff with PVL-SA
All staff management done via occupational health
Active Infection
- HCWs should not work with infected skin or purulent eye lesions
- All cuts and grazes must be covered
- Report all lesions promptly to Occupational Health Service
Return to Work Criteria
HCW with proven PVL-SA infection should not work until:
- Acute infection has resolved
- 48 hours of five-day decolonisation regimen completed
Contact/Family Management
- Make enquiries in close contact with staff member
- Families can be treated simultaneously if required
Follow-up Screening
- As per MRSA guidelines: three screens, one week apart
- Re-colonisation may occur from community contact
- Staff must stop working if further skin lesions develop
Decolonisation Failure
If staff remains carrier despite two courses of treatment:
- May continue work if not implicated in hospital transmission
- Must cease working immediately if infected skin lesion develops
Community Activity Restrictions
Avoid until lesions healed:
• Gyms, saunas, swimming pools
• Massage, manicure facilities
• Other communal/recreational settings where lesions cannot be adequately covered
